Clinical trials: Growth Failure
Growth Failure, Enteropathy
Environmental Enteropathy Among Infants and Children With Growth Faltering
The study was conducted on 200 patients with growth faltering on 2 phases. In the first phase the patient received nutritional rehabilitation with polymeric formula for 12 weeks then they were reassessed by anthropometric…
- Trial name
- NCT06497907
- Testing
- polymeric formula, peptide based formula
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.
- Conditions
- Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
- Trial name
- NCT05338970
- Testing
- Patritumab Deruxtecan, Platinum-based chemotherapy
- Where
- 182 sites in United States, Australia and 19 more
- Volunteers
- 586 people
- Sponsor
- Daiichi Sankyo
Growth Failure, Preterm Birth
Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants
The goal of this clinical trial is to ascertain whether oropharyngeal administration of colostrum contributes to postnatal growth in very preterm infants (those born before 32 weeks of gestation).
- Conditions
- Growth Failure, Preterm Birth, Microbiota
- Trial name
- IOCOIOPGIPI (NCT07082881)
- Testing
- Colostrum, Normal Saline
- Volunteers
- 220 people
- Sponsor
- Suqian First Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and…
- Trial name
- MARIPOSA-2 (NCT04988295)
- Testing
- Lazertinib, Amivantamab, Pemetrexed
- Where
- 249 sites in United States, Argentina and 27 more
- Volunteers
- 776 people
- Sponsor
- Janssen Research & Development, LLC
Maternal Malnutrition, Growth Failure
Women First: Preconception Maternal Nutrition
Multi-country three-arm, individually randomized, non-masked, controlled trial to ascertain the benefits of ensuring optimal maternal nutrition before conception and providing an evidence base for programmatic priority directed…
- Conditions
- Maternal Malnutrition, Growth Failure, Mortality, Morbidity
- Trial name
- WF (NCT01883193)
- Testing
- Comprehensive Maternal Nutrition Intervention
- Where
- 4 sites in Democratic Republic of the Congo, Guatemala and 2 more
- Volunteers
- 7,374 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
HIV Infections
Growth Hormone Treatment of Children With HIV-Associated Growth Failure
The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children.
- Trial name
- NCT00006143
- Testing
- Somatropin
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Kidney Disease, End-Stage Renal Disease
Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis
This trial is conducted in Europe. The aim of this trial is to to compare steady-state total growth hormone (GH) exposure in haemodialysis (HD) patients with that of matched healthy subjects.
- Conditions
- Chronic Kidney Disease, End-Stage Renal Disease, Healthy
- Trial name
- NCT01502137
- Testing
- somatropin
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Pediatric Growth Hormone Deficiency
Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
This non-interventional study will be performed by design of post-marketing surveillance (PMS) as an additional pharmacovigilance activity of the Risk Management Plan (RMP) for Ngenla® pre-filled pen injection, which is required…
- Trial name
- NCT05509894
- Testing
- Ngenla
- Where
- South Korea
- Volunteers
- 565 people
- Sponsor
- Pfizer
Bone Loss, Alveolar, Resorption, Bone
The Effect of Growth Factor on Implant Osseointegration
In this study, concentrated growth factor obtained by centrifuging the patient's own blood and advanced platelet-rich fibrin liquids were applied to the implant cavity and surface.
- Conditions
- Bone Loss, Alveolar, Resorption, Bone, Osseointegration Failure of Dental Implant
- Trial name
- NCT04879446
- Testing
- Concentrated growth factor(CGF), Advanced platelet rich fibrin (A-PRF), Control side of concentrated growth factor study group
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Uğur Can ÜNLÜGENÇ
Non-small Cell Lung Cancer
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated…
- Trial name
- NCT02322281
- Testing
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 149 people
- Sponsor
- Clovis Oncology, Inc.
Cardiovascular Diseases, Heart Diseases
Epidemiology of Insulin Growth Factor (IGF) and Cardiovascular Events
To explore the role of insulin growth factor in cardiovascular disease in older men and women.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction
- Trial name
- NCT00086424
- Volunteers
- 5,888 people
- Sponsor
- Albert Einstein College of Medicine
Failure to Thrive
Cyproheptadine as an Appetite Stimulant
Cyproheptadine is currently clinically used as an appetite stimulant for children with failure to thrive without underlying organic disease.
- Trial name
- NCT01314989
- Testing
- Cyproheptadine, Sugar pill
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- St. Justine's Hospital
Failure to Thrive, Infections
The Effect of Lactoferrin in High Calorie Formula on IL-6 and IL10 in Children With Failure to Thrive and Infection
Lactoferrin is an iron-binding glycoprotein of the transferrin family which is expressed and refers to it as a "red protein from milk".
- Trial name
- Interleukin (NCT05289674)
- Testing
- High Calorie Formula
- Where
- Indonesia
- Volunteers
- 75 people
- Sponsor
- Universitas Airlangga
Prematurity; Extreme, Failure to Thrive in Newborn
Targeted Fortification of Donor Breast Milk in Preterm Infants
This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants.
- Conditions
- Prematurity; Extreme, Failure to Thrive in Newborn, Growth Retardation, Growth Failure
- Trial name
- NCT04294368
- Testing
- Similac Human Milk Fortifier Extensively Hydrolyzed Protein Concentrated Liquid, Similac Liquid Protein Fortifier, Nestle Microlipid
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Growth Disorders, Growth Failure
Is There a Microbiome Associated With Poor Growth in Preterm Infants?
This study evaluates the relationship between growth and stool microbiota in premature infants.
- Conditions
- Growth Disorders, Growth Failure, Prematurity
- Trial name
- NCT03761498
- Testing
- Caloric Requirement
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Texas Southwestern Medical Center
Infant Malnutrition, Malnutrition in Pregnancy
Supplementing Maternal and Infant Diet With High-energy, Micronutrient Fortified Lipid-based Nutrient Supplements (LNS)
The use of lipid-based nutrients (LNS), such as Nutributter or fortified spread (FS), have been associated with improved growth and development outcomes among infants in Ghana and Malawi.
- Trial name
- iLiNS-DYAD-M (NCT01239693)
- Testing
- IFA, MMN, LNS
- Where
- Malawi
- Volunteers
- 1,391 people, healthy volunteers welcome
- Sponsor
- Tampere University
HIV Infections
A Study of Megestrol Acetate in HIV-Infected Children
The purpose of this study is to see if megestrol acetate is safe and effective in treating HIV-infected children with failure to thrive (FTT).
- Trial name
- NCT00002182
- Testing
- Megestrol acetate
- Where
- Puerto Rico
- Volunteers
- 25 people
- Sponsor
- Gamma Project - ACTU
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature…
- Trial name
- NCT00125164
- Testing
- rhIGF-1 (mecasermin, Tercica, Inc.)
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Ipsen
Growth Hormone Deficiency
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
- Trial name
- SkyPASS (NCT05775523)
- Testing
- No intervention
- Where
- 27 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S